



(43) International Publication Date
14 November 2013 (14.11.2013)

(10) International Publication Number
WO 2013/168016 A1

(51) International Patent Classification:

C07F 9/09 (2006.01) A61P 3/00 (2006.01)
C07C 309/63 (2006.01) A61P 3/10 (2006.01)
A61K 31/683 (2006.01)

(21) International Application Number:

PCT/IB2013/051596

(22) International Filing Date:

28 February 2013 (28.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1853/CHE/2012 10 May 2012 (10.05.2012) IN

(72) Inventor; and

(71) Applicant : KANDULA, Mahesh [IN/IN]; Door No. 11-61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME

(57) Abstract: The invention discloses the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) or formula (II), and the methods of treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup or injection. The compositions may be used to treat fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, insulin resistance, high blood pressure, central obesity, overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver progressing to NAFLD, polycystic ovarian syndrome, hypophosphatemia, renal diseases, albuminuria, end stage renal disease and acanthosis nigricans.



WO 2013/168016 A1